KLK3 and benign prostatic hyperplasia: While our series is small, it builds on a body of evidence of the utility of alternative biomarkers to the commonly used PSA that may one day be able to help supplant the need for invasive biopsy for diagnosis, as well as potentially predict or provide prognostic indication for disease aggressiveness or to determine the presence of BPH.